Dabigatran versus Warfarin in Patients with Mechanical Heart Valves
John W. Eikelboom(King's College Hospital), Frans Van de Werf, Yasser Khder(Boehringer Ingelheim (France)), Christopher B. Granger(Duke University), Maarten L. Simoons(Goethe University Frankfurt), A. Pieter Kappetein(Erasmus MC), Martina Brueckmann, Jens‐Uwe Voigt(University of Baltimore), Michael J. Mack(Baylor Scott & White Health), Kelly Guiver(Boehringer Ingelheim (United Kingdom)), Kevin Devenny(Boehringer Ingelheim (United Kingdom)), Stuart J. Connolly(Population Health Research Institute), Jon Blatchford(Boehringer Ingelheim (United Kingdom)), Ruth Harper(Boehringer Ingelheim (United Kingdom)), Jeffrey Friedman(Boehringer Ingelheim (United States)), Hugo Maas(Boehringer Ingelheim (Germany)), Maximilian T. Lobmeyer(Boehringer Ingelheim (Germany))
Cited by 1,496
Related Papers
Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
|Journal of the American Society of Echocardiography|2015|18k
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
|European Heart Journal - Cardiovascular Imaging|2015|8.3k
Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients
|New England Journal of Medicine|2019|4.7k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k